Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Q4-FY26"

9 News Found

From losses to lift-off: Astec gains ground in Q4 FY26
News | April 28, 2026

From losses to lift-off: Astec gains ground in Q4 FY26

The company reported consolidated total income of Rs. 161.3 crore in Q4 FY26, a strong jump from Rs. 120.3 crore in the same period last year


Orchid Pharma submits Q4 FY26 SEBI compliance certificate to NSE, BSE
News | April 11, 2026

Orchid Pharma submits Q4 FY26 SEBI compliance certificate to NSE, BSE

Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter


Dabur reports steady domestic growth amid global headwinds in Q4 FY26
News | April 08, 2026

Dabur reports steady domestic growth amid global headwinds in Q4 FY26

The India FMCG business showed a sequential recovery and is expected to post high-single digit growth


RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth
News | April 30, 2026

RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth

In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth


Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr
News | April 30, 2026

Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr

Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities


Pharma stocks face Q4 reality check amid global headwinds
News | April 20, 2026

Pharma stocks face Q4 reality check amid global headwinds

Analysts expect modest revenue growth but pressure on profitability in the March quarter


Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth
News | February 13, 2026

Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth

The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25


Cupid’s B2B export order book stands at Rs. 100 Cr+
News | September 04, 2025

Cupid’s B2B export order book stands at Rs. 100 Cr+

These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI


Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr
News | August 08, 2025

Hikal reports Q1 FY26 consolidated loss of Rs. 22.4 Cr

Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025